Angiotensin II type 1 receptor antagonists in the treatment of hypertension in elderly patients: focus on patient outcomes

References

• ElliottWJManagement of hypertension in the very elderly patientHypertension200444680080415505119
   PubMed Web of Science ®Google Scholar
• KearneyPMWheltonMReynoldsKMuntnerPWheltonPKHeJGlobal burden of hypertension: analysis of worldwide dataLancet2005365945521722315652604
   PubMed Web of Science ®Google Scholar
• VasanRSBeiserASeshadriSResidual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart StudyJAMA200228781003101011866648
   PubMed Web of Science ®Google Scholar
• LakattaEGArterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part III: cellular and molecular clues to heart and arterial agingCirculation2003107349049712551876
   PubMed Web of Science ®Google Scholar
• BeckettNSPetersRFletcherAETreatment of hypertension in patients 80 years of age or olderN Engl J Med2008358181887189818378519
   PubMed Web of Science ®Google Scholar
• StaessenJAFagardRThijsLRandomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial InvestigatorsLancet199735090807577649297994
   PubMed Web of Science ®Google Scholar
• DahlofBLindholmLHHanssonLScherstenBEkbomTWesterPOMorbidity and mortality in the Swedish trial in old patients with hypertension (STOP-hypertension)Lancet19913388778128112851682683
   PubMed Web of Science ®Google Scholar
• Medical Research Council European trial of chorion villus samplingMRC working party on the evaluation pf chorion villus samplingLancet19913378756149114991675367
   PubMedGoogle Scholar
• SHEP Cooperative Research GroupPrevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP)JAMA199126524325532642046107
   PubMed Web of Science ®Google Scholar
• IsrailiZHHallWDACE inhibitors. Differential use in elderly patients with hypertensionDrugs Aging1995753553718573991
   PubMed Web of Science ®Google Scholar
• SvanborgAAge-related changes in cardiac physiology. Can they be postponed or treated by drugs?Drugs Aging19971064634729205851
   PubMed Web of Science ®Google Scholar
• CleophasTJvan MarumRAge-related decline in autonomic control of blood pressure: implications for the pharmacological management of hypertension in the elderlyDrugs Aging200320531331912696992
   PubMed Web of Science ®Google Scholar
• ChobanianAVBakrisGLBlackHRSeventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureHypertension20034261206125214656957
   PubMed Web of Science ®Google Scholar
• ManciaGde BackerGDominiczakA2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)Eur Heart J200728121462153617562668
   PubMed Web of Science ®Google Scholar
• KalraSKalraBAgrawalNCombination therapy in hypertension: an updateDiabetol Metab Syndr2010214420576135
   PubMed Web of Science ®Google Scholar
• WrightJMLeeCHChambersGKSystematic review of antihypertensive therapies: does the evidence assist in choosing a first-line drug?CMAJ19991611253210420860
   PubMed Web of Science ®Google Scholar
• ChobanianAVBakrisGLBlackHRThe seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 reportJAMA2003289192560257212748199
   PubMed Web of Science ®Google Scholar
• OgiharaTRakugiHHypertension in the elderly: a Japanese perspectiveDrugs Aging200522429731415839719
   PubMed Web of Science ®Google Scholar
• HallerHEffective management of hypertension with dihydropyridine calcium channel blocker-based combination therapy in patients at high cardiovascular riskInt J Clin Pract200862578179018355239
   PubMed Web of Science ®Google Scholar
• HillemanDELucasBDJrAngiotensin-converting enzyme inhibitors and stroke risk: benefit beyond blood pressure reduction?Pharmacotherapy20042481064107615338854
   PubMed Web of Science ®Google Scholar
• BangaloreSMesserliFHKostisJBPepineCJCardiovascular protection using beta-blockers: a critical review of the evidenceJ Am Coll Cardiol200750756357217692739
   PubMed Web of Science ®Google Scholar
• FlegJLAronowWSFrishmanWHCardiovascular drug therapy in the elderly: benefits and challengesNat Rev Cardiol201011620213930
   PubMed Web of Science ®Google Scholar
• WernerCBaumhakelMTeoKKRAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selectionClin Res Cardiol200897741843118454336
   PubMed Web of Science ®Google Scholar
• WeberMAchieving blood pressure goals: should angiotensin II receptor blockers become first-line treatment in hypertension?J Hypertens Suppl2009275S9S1419587555
   PubMedGoogle Scholar
• CooneyDPascuzziKPolypharmacy in the elderly: focus on drug interactions and adherence in hypertensionClin Geriatr Med200925222123319555869
   PubMed Web of Science ®Google Scholar
• CovicAGusbeth-TatomirPThe role of the renin-angiotensin-aldosterone system in renal artery stenosis, renovascular hypertension, and ischemic nephropathy: diagnostic implicationsProg Cardiovasc Dis200952320420819917331
   PubMed Web of Science ®Google Scholar
• TurgutFBalogunRAAbdel-RahmanEMRenin-angiotensin-aldosterone system blockade effects on the kidney in the elderly: benefits and limitationsClin J Am Soc Nephrol2010571330133920498247
   PubMed Web of Science ®Google Scholar
• SiragyHMCareyRMRole of the intrarenal renin-angiotensin-aldosterone system in chronic kidney diseaseAm J Nephrol201031654155020484892
   PubMed Web of Science ®Google Scholar
• BelminJLevyBIMichelJBChanges in the renin-angiotensin-aldosterone axis in later lifeDrugs Aging1994553914007833591
   PubMed Web of Science ®Google Scholar
• TsunodaKAbeKGotoTEffect of age on the renin-angiotensin-aldosterone system in normal subjects: simultaneous measurement of active and inactive renin, renin substrate, and aldosterone in plasmaJ Clin Endocrinol Metab19866223843893510226
   PubMed Web of Science ®Google Scholar
• SchiffrinELTouyzRMMultiple actions of angiotensin II in hypertension: benefits of AT1 receptor blockadeJ Am Coll Cardiol200342591191312957442
   PubMed Web of Science ®Google Scholar
• KaschinaEUngerTAngiotensin AT1/AT2 receptors: regulation, signalling and functionBlood Press2003122708812797627
   PubMed Web of Science ®Google Scholar
• BenigniACassisPRemuzziGAngiotensin II revisited: new roles in inflammation, immunology and agingEMBO Mol Med20102724725720597104
   PubMed Web of Science ®Google Scholar
• YamamotoRAkazawaHItoKAngiotensin II type 1a receptor signals are involved in the progression of heart failure in MLP-deficient miceCirc J200771121958196418037754
   PubMed Web of Science ®Google Scholar
• SasakiTKuzuyaMNakamuraKAT1 blockade attenuates atherosclerotic plaque destabilization accompanied by the suppression of cathepsin S activity in apoE-deficient miceAtherosclerosis2010210243043720079903
   PubMed Web of Science ®Google Scholar
• EhrlichJRNattelSNovel approaches for pharmacological management of atrial fibrillationDrugs200969775777419441867
   PubMed Web of Science ®Google Scholar
• TadevosyanAMaguyAVilleneuveLRNuclear-delimited angiotensin receptor-mediated signaling regulates cardiomyocyte gene expressionJ Biol Chem201028529223382234920463030
   PubMed Web of Science ®Google Scholar
• BilletSAguilarFBaudryCClauserERole of angiotensin II AT1 receptor activation in cardiovascular diseasesKidney Int200874111379138418650793
   PubMed Web of Science ®Google Scholar
• SkeggsLTJrKahnJRLentzKShumwayNPThe preparation, purification, and amino acid sequence of a polypeptide renin substrateJ Exp Med1957106343945313463253
   PubMed Web of Science ®Google Scholar
• KatragaddaSAroraRRRole of angiotensin-converting enzyme inhibitors in vascular modulation: beyond the hypertensive effectsAm J Ther2010171e11e2320090429
   PubMedGoogle Scholar
• MorathCSchmiedBMehrabiAAngiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers after renal transplantationClin Transplant200923Suppl 21333619930314
   PubMed Web of Science ®Google Scholar
• BrownNJVaughanDEAngiotensin-converting enzyme inhibitorsCirculation19989714141114209577953
   PubMed Web of Science ®Google Scholar
• IsrailiZHHallWDCough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiologyAnn Intern Med199211732342421616218
   PubMed Web of Science ®Google Scholar
• WooKSNichollsMGHigh prevalence of persistent cough with angiotensin converting enzyme inhibitors in ChineseBr J Clin Pharmacol19954021411448562296
   PubMed Web of Science ®Google Scholar
• OsIBratlandBDahlofBGisholtKSyvertsenJOTretliSFemale sex as an important determinant of lisinopril-induced coughLancet199233987893721346451
   PubMed Web of Science ®Google Scholar
• HooverTLippmannMGrouzmannEMarceauFHerscuPAngiotensin converting enzyme inhibitor induced angiooedema: a review of the pathophysiology and risk factorsClin Exp Allergy2010401506119659669
   PubMed Web of Science ®Google Scholar
• BrownNJRayWASnowdenMGriffinMRBlack Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedemaClin Pharmacol Ther19966018138689816
   PubMed Web of Science ®Google Scholar
• SlaterEEMerrillDDGuessHAClinical profile of angioedema associated with angiotensin converting-enzyme inhibitionJAMA198826079679702840522
   PubMed Web of Science ®Google Scholar
• TomlinsonBYoungRPChanJCChanTYCritchleyJAPharmacoepidemiology of ACE inhibitor–induced coughDrug Saf19971621501519067125
   PubMed Web of Science ®Google Scholar
• McInnesGTO’KaneKPIstadHKeinanen-KiukaanniemiSvan MierloHFComparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patientsJ Hum Hypertens200014426326910805052
   PubMed Web of Science ®Google Scholar
• GoaKLWagstaffAJLosartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertensionDrugs19965158208458861549
   PubMed Web of Science ®Google Scholar
• SimpsonKLMcClellanKJLosartan: a review of its use, with special focus on elderly patientsDrugs Aging200016322725010803861
   PubMed Web of Science ®Google Scholar
• UngerTPharmacology of AT1-receptor blockersBlood Press Suppl2001351011683476
   PubMedGoogle Scholar
• TurnbullFBlood Pressure Lowering Treatment Trialists’ CollaborationEffects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trialsLancet200336293951527153514615107
   PubMed Web of Science ®Google Scholar
• LawMRMorrisJKWaldNJUse of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studiesBMJ2009338b166510.1136/bmj.b166519454737
   PubMed Web of Science ®Google Scholar
• GradmanAHPapademetriouVCombined renin-angiotensin-aldosterone system inhibition in patients with chronic heart failure secondary to left ventricular systolic dysfunctionAm Heart J2009157Suppl 6S17S2319450720
   PubMed Web of Science ®Google Scholar
• FrancisGSCohnJNJohnsonGRectorTSGoldmanSSimonAPlasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies GroupCirculation199387Suppl 6VI40VI488500238
   PubMed Web of Science ®Google Scholar
• RieggerGABouzoHPetrPImprovement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) InvestigatorsCirculation1999100222224223010577995
   PubMed Web of Science ®Google Scholar
• CohnJNRationale for angiotensin II receptor blocker therapy in chronic heart failureJ Renin Angiotensin Aldosterone Syst20001Suppl 2S38S4017199220
   PubMedGoogle Scholar
• MaggioniAPAnandIGottliebSOLatiniRTognoniGCohnJNEffects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitorsJ Am Coll Cardiol20024081414142112392830
   PubMed Web of Science ®Google Scholar
• PittBSegalRMartinezFARandomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)Lancet199734990547477529074572
   PubMed Web of Science ®Google Scholar
• PittBPoole-WilsonPASegalREffect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial–the Losartan Heart Failure Survival Study ELITE IILancet200035592151582158710821361
   PubMed Web of Science ®Google Scholar
• CohnJNTognoniGValsartan Heart Failure Trial InvestigatorsA randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failureN Engl J Med2001345231667167511759645
   PubMed Web of Science ®Google Scholar
• DicksteinKELITE II and Val-HeFT are different trials: together what do they tell us?Curr Control Trials Cardiovasc Med20012524024311806803
   PubMedGoogle Scholar
• PfefferMASwedbergKGrangerCBEffects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programmeLancet2003362938675976613678868
   PubMed Web of Science ®Google Scholar
• GrangerCBMcMurrayJJYusufSEffects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trialLancet2003362938677277613678870
   PubMed Web of Science ®Google Scholar
• McMurrayJJOstergrenJSwedbergKEffects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trialLancet2003362938676777113678869
   PubMed Web of Science ®Google Scholar
• YusufSPfefferMASwedbergKEffects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved TrialLancet2003362938677778113678871
   PubMed Web of Science ®Google Scholar
• DicksteinKKjekshusJOPTIMAAL Steering Committee of the OPTIMAAL Study GroupEffects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal trial in myocardial infarction with angiotensin II antagonist losartanLancet2002360933575276012241832
   PubMed Web of Science ®Google Scholar
• PfefferMAMcMurrayJJVelazquezEJValsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or bothN Engl J Med2003349201893190614610160
   PubMed Web of Science ®Google Scholar
• YusufSTeoKKPogueJTelmisartan, ramipril, or both in patients at high risk for vascular eventsN Engl J Med2008358151547155918378520
   PubMed Web of Science ®Google Scholar
• YusufSTeoKAndersonCEffects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trialLancet200837296441174118318757085
   PubMed Web of Science ®Google Scholar
• UngerJParkinCGType 2 diabetes: an expanded view of pathophysiology and therapyPostgrad Med2010122314515720463424
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study GroupTight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38BMJ199831771607037139732337
   PubMed Web of Science ®Google Scholar
• RuilopeLMAngiotensin receptor blockers: RAAS blockade and renoprotectionCurr Med Res Opin20082451285129318366863
   PubMed Web of Science ®Google Scholar
• SiamopoulosKCKalaitzidisRGInhibition of the renin-angiotensin system and chronic kidney diseaseInt Urol Nephrol20084041015102518704745
   PubMed Web of Science ®Google Scholar
• ParvingHHLehnertHBrochner-MortensenJGomisRAndersenSArnerPThe effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetesN Engl J Med20013451287087811565519
   PubMed Web of Science ®Google Scholar
• LewisEJHunsickerLGClarkeWRRenoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetesN Engl J Med20013451285186011565517
   PubMed Web of Science ®Google Scholar
• BrennerBMCooperMEde ZeeuwDEffects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathyN Engl J Med20013451286186911565518
   PubMed Web of Science ®Google Scholar
• VibertiGWheeldonNMMicroAlbuminuria Reduction With VALsartan (MARVAL) Study InvestigatorsMicroalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effectCirculation2002106667267812163426
   PubMed Web of Science ®Google Scholar
• ScheenAJPrevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin systemDrugs200464222537256515516153
   PubMed Web of Science ®Google Scholar
• DerosaGCiceroAFD’AngeloATelmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alphaHypertens Res2006291184985617345784
   PubMed Web of Science ®Google Scholar
• NagelJMTietzABGokeBParhoferKGThe effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjectsMetabolism20065591149115416919531
   PubMed Web of Science ®Google Scholar
• WiernspergerNVascular defects in the aetiology of peripheral insulin resistance in diabetes. A critical review of hypotheses and factsDiabetes Metab Rev19941032873077835173
   PubMed Web of Science ®Google Scholar
• ElliottWJMeyerPMIncident diabetes in clinical trials of antihypertensive drugs: a network meta-analysisLancet2007369955720120717240286
   PubMed Web of Science ®Google Scholar
• American Diabetes AssociationStandards of medical care in diabetes–2010Diabetes Care201033Suppl 1S11S6120042772
   PubMed Web of Science ®Google Scholar
• DahlofBDevereuxRBKjeldsenSECardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololLancet20023599311995100311937178
   PubMed Web of Science ®Google Scholar
• LindholmLHIbsenHDahlofBCardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololLancet200235993111004101011937179
   PubMed Web of Science ®Google Scholar
• DevereuxRBLylePALosartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) studyExpert Opin Pharmacother20045112311232015500378
   PubMed Web of Science ®Google Scholar
• JuliusSAldermanMHBeeversGCardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE studyJ Am Coll Cardiol20044361047105515028365
   PubMed Web of Science ®Google Scholar
• LithellHHanssonLSkoogIThe Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trialJ Hypertens200321587588612714861
   PubMed Web of Science ®Google Scholar
• PapademetriouVFarsangCElmfeldtDStroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE)J Am Coll Cardiol20044461175118015364316
   PubMed Web of Science ®Google Scholar
• ChobanianAVClinical practice. Isolated systolic hypertension in the elderlyN Engl J Med2007357878979617715411
   PubMed Web of Science ®Google Scholar
• JuliusSKjeldsenSEWeberMOutcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trialLancet200436394262022203115207952
   PubMed Web of Science ®Google Scholar
• LindholmLHPerssonMAlaupovicPCarlbergBSvenssonASamuelssonOMetabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study)J Hypertens20032181563157412872052
   PubMed Web of Science ®Google Scholar
• McKelvieRSYusufSPericakDComparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study InvestigatorsCirculation1999100101056106410477530
   PubMed Web of Science ®Google Scholar
• HallWDMontoroRLittlejohnTJainAFelicianoNZhengHEfficacy and tolerability of valsartan in combination with hydrochlorothiazide in essential hypertensionClin Drug Investig1998163203210
   Web of Science ®Google Scholar
• CritchleyLAHypotension, subarachnoid block and the elderly patientAnaesthesia19965112113911439038450
   PubMed Web of Science ®Google Scholar
• GillisJCMarkhamAIrbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertensionDrugs19975468859029421695
   PubMed Web of Science ®Google Scholar
• MarkhamAGoaKLValsartan. A review of its pharmacology and therapeutic use in essential hypertensionDrugs19975422993119257084
   PubMed Web of Science ®Google Scholar
• WeirMRAre drugs that block the renin-angiotensin system effective and safe in patients with renal insufficiency?Am J Hypertens19991212 Pt 3195S203S10619572
   PubMed Web of Science ®Google Scholar
• BurnierMBrunnerHRAngiotensin II receptor antagonistsLancet2000355920463764510696996
   PubMed Web of Science ®Google Scholar
• AntoniouTGomesTJuurlinkDNLoutfyMRGlazierRHMamdaniMMTrimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based studyArch Intern Med2010170121045104920585070
   PubMedGoogle Scholar
• PuigJGMateosFBunoAOrtegaRRodriguezFDal-ReREffect of eprosartan and losartan on uric acid metabolism in patients with essential hypertensionJ Hypertens19991771033103910419078
   PubMed Web of Science ®Google Scholar
• CsajkaCBuclinTBrunnerHRBiollazJPharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonistsClin Pharmacokinet19973211299012554
   PubMed Web of Science ®Google Scholar
• SipahiIDebanneSMRowlandDYSimonDIFangJCAngiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trialsLancet Oncol201011762763620542468
   PubMed Web of Science ®Google Scholar
• GoldsteinMRMascitelliLPezzettaFAngiotensin-receptor blockade, cancer, and concernsLancet Oncol201011819
   Web of Science ®Google Scholar
• BöhmMLaufsUPfreundschuhMComment on: Angiotensinreceptor blockade and risk of cancer: meta-analysis of randomised controlled trialsLancet Oncol20101181820816376
   PubMed Web of Science ®Google Scholar
• MeredithPAMcInnesGTComment on: Angiotensinreceptor blockade and risk of cancer: meta-analysis of randomised controlled trialsLancet Oncol20101181920816377
   PubMed Web of Science ®Google Scholar
• SharpeMJarvisBGoaKLTelmisartan: a review of its use in hypertensionDrugs200161101501152911558835
   PubMed Web of Science ®Google Scholar
• TaavitsainenPKiukaanniemiKPelkonenOIn vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonistsEur J Clin Pharmacol200056213514010877007
   PubMed Web of Science ®Google Scholar
• MarinoMRVachharajaniNNDrug interactions with irbesartanClin Pharmacokinet200140860561411523726
   PubMed Web of Science ®Google Scholar
• CodyRJPhysiological changes due to age. Implications for drug therapy of congestive heart failureDrugs Aging1993343203348369592
   PubMed Web of Science ®Google Scholar
• MorganDJBrayKMLean body mass as a predictor of drug dosage. Implications for drug therapyClin Pharmacokinet19942642923078013162
   PubMed Web of Science ®Google Scholar
• TurnheimKDrug dosage in the elderly. Is it rational?Drugs Aging19981353573799829164
   PubMed Web of Science ®Google Scholar
• FuANairKSAge effect on fibrinogen and albumin synthesis in humansAm J Physiol19982756 Pt 1E1023E10309843745
   PubMedGoogle Scholar
• IsrailiZHDaytonPGHuman alpha-1-glycoprotein and its interactions with drugsDrug Metab Rev200133216123511495502
   PubMed Web of Science ®Google Scholar
• UngerTKaschinaEDrug interactions with angiotensin receptor blockers: a comparison with other antihypertensivesDrug Saf2003261070772012862505
   PubMed Web of Science ®Google Scholar
• WaldmeierFFleschGMullerPPharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral doseXenobiotica199727159719041679
   PubMed Web of Science ®Google Scholar
• RuilopeLJagerBEprosartan for the treatment of hypertensionExpert Opin Pharmacother20034110711412517247
   PubMed Web of Science ®Google Scholar
• TeneroDMMartinDEMillerAKEffect of age and gender on the pharmacokinetics of eprosartanBr J Clin Pharmacol19984632672709764969
   PubMed Web of Science ®Google Scholar
• UchidaSWatanabeHNishioSAltered pharmacokinetics and excessive hypotensive effect of candesartan in a patient with the CYP2C91/3 genotypeClin Pharmacol Ther200374550550814586391
   PubMed Web of Science ®Google Scholar
• MallionJSicheJLacourciereYABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertensionJ Hum Hypertens1999131065766410516734
   PubMed Web of Science ®Google Scholar
• WhiteWBAnwarYAMansoorGASicaDAEvaluation of the 24-hour blood pressure effects of eprosartan in patients with systemic hypertensionAm J Hypertens200114121248125511775134
   PubMed Web of Science ®Google Scholar
• HubnerRHogemannAMSunzelMRiddellJGPharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteersJ Hum Hypertens199711Suppl 2S19S259331000
   PubMed Web of Science ®Google Scholar
• SioufiAMarfilFJaouenAThe effect of age on the pharmacokinetics of valsartanBiopharm Drug Dispos19981942372449604123
   PubMed Web of Science ®Google Scholar
• VachharajaniNNShyuWCSmithRAGreeneDSThe effects of age and gender on the pharmacokinetics of irbesartanBr J Clin Pharmacol19984666116139862252
   PubMed Web of Science ®Google Scholar
• von BergmannKLaeisPPuchlerKSudhopTSchwochoLRGonzalezLOlmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomilJ Hypertens Suppl2001191S33S4011451213
   PubMedGoogle Scholar
• McClellanKJMarkhamATelmisartanDrugs199856610391044 discussion104510469878991
   PubMed Web of Science ®Google Scholar
• StangierJSuCASchondorferGRothWPharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteersJ Clin Pharmacol20004012 Pt 11355136411185634
   PubMed Web of Science ®Google Scholar
• ThurmannPAValsartan: a novel angiotensin type 1 receptor antagonistExpert Opin Pharmacother20001233735011249553
   PubMedGoogle Scholar
• GleiterCHMorikeKEClinical pharmacokinetics of candesartanClin Pharmacokinet200241171711825094
   PubMed Web of Science ®Google Scholar
• BrousilJABurkeJMOlmesartan medoxomil: an angiotensin II-receptor blockerClin Ther20032541041105512809956
   PubMed Web of Science ®Google Scholar
• SchepkeMWernerEBieckerEHemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertensionGastroenterology2001121238939511487548
   PubMed Web of Science ®Google Scholar
• BurnierMAngiotensin II type 1 receptor blockersCirculation2001103690491211171802
   PubMed Web of Science ®Google Scholar
• WeirMRDiabetes and hypertension: how low should you go and with which drugs?Am J Hypertens2001145 Pt 217S26S11370956
   PubMed Web of Science ®Google Scholar
• CuspidiCNegriFZanchettiAAngiotensin II receptor blockers and cardiovascular protection: focus on left ventricular hypertrophy regression and atrial fibrillation preventionVasc Health Risk Manag200841677318629360
   PubMedGoogle Scholar
• HanesDSWeirMRUsefulness of ARBs and ACE inhibitors in the prevention of vascular dementia in the elderlyAm J Geriatr Cardiol200716317518217483670
   PubMedGoogle Scholar
• European Society of Hypertension-European Society of Cardiology Guidelines Committee2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertensionJ Hypertens20032161011105312777938
   PubMed Web of Science ®Google Scholar
• SimkoFSimkoJFabryovaMACE-inhibition and angiotensin II receptor blockers in chronic heart failure: pathophysiological consideration of the unresolved battleCardiovasc Drugs Ther200317328729014669746
   PubMedGoogle Scholar
• PloskerGLFosterRHEprosartan: a review of its use in the management of hypertensionDrugs200060117720110929934
   PubMed Web of Science ®Google Scholar
• BottorffMBTeneroDMPharmacokinetics of eprosartan in healthy subjects, patients with hypertension, and special populationsPharmacotherapy1999194 Pt 273S78S10213525
   PubMed Web of Science ®Google Scholar
• McClellanKJBalfourJAEprosartanDrugs1998555713718 discussion7197209585867
   PubMed Web of Science ®Google Scholar
• TeneroDMartinDChapelskyMEffect of hepatic disease on the pharmacokinetics and plasma protein binding of eprosartanPharmacotherapy199818142509469680
   PubMed Web of Science ®Google Scholar
• MarkhamASpencerCMJarvisBIrbesartan: an updated review of its use in cardiovascular disordersDrugs20005951187120610852648
   PubMed Web of Science ®Google Scholar
• MarinoMRLangenbacherKMRaymondRHFordNFLasseterKCPharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosisJ Clin Pharmacol19983843473569590462
   PubMed Web of Science ®Google Scholar
• WarnerGTJarvisBOlmesartan medoxomilDrugs200262913451353 discussion1354135612076183
   PubMed Web of Science ®Google Scholar
• KaramyanVTSpethRCEnzymatic pathways of the brain renin-angiotensin system: unsolved problems and continuing challengesRegul Pept20071431–3152717493693
   PubMedGoogle Scholar
• SaseenJJMacLaughlinEJHypertensionDiPiroJTTalbertRLYeeGRMatzkeGRWellsBGPoseyLMPharmacotherapy: a Pathophysiologic Approach7th edMcGraw-Hill Companies, Inc.2008139171
   Google Scholar